24 November 2020 | News
Focuses on innovative oncology medicines adopts a differentiated combinatory and complementary R&D approach to discover, develop and commercialize
Image Caption: Antengene's listing ceremony in Shanghai: Dr. Jay Mei (Left); Mr. Yiteng Liu (Right)
Antengene Corporation Limited, a clinical-stage biopharmaceutical company with integrated drug discovery, clinical development, anchored in Asia-Pacific (APAC) with a global layout, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") on 20 Nov 2020.
The total number of offer shares under the Global Offering amounts to 154,153,500 shares, with the final offer price determined at HK$18.08 per offer share. The net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and expenses paid and payable by the Company in connection with the Global Offering, are estimated to be approximately HK$2,635.9 million.
Antengene, which focuses on innovative oncology medicines, adopts a differentiated combinatory and complementary R&D approach to discover, develop and commercialize global first-in-class, only-in-class and/or best-in-class therapies, in order to fully unlock their therapeutic potential. As of the latest practicable date, the Company had built a highly selective pipeline of 12 drug assets focused on oncology, in which one of the Company's core products, ATG-010 (selinexor) or XPOVIO (selinexor), is a first-in-class and only-in-class selective inhibitor of nuclear export (SINE) compound that inhibits the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus and selective induction of apoptosis in cancer cells. Currently, the Company has initiated two Phase II registrational clinical trials for R/R MM and R/R DLBCL and will leverage the data from the clinical trials carried out by Karyopharm (a global pharmaceutical company listed on NASDAQ) to submit the new drug application (NDA) for ATG-010 (selinexor) by 2021 directly in certain APAC countries or territories where NDA approval may be obtained without additional clinical trials, including Australia, Singapore, Hong Kong, South Korea, Taiwan and Thailand.
Dr. Mei said, "Today marked a milestone in Antengene's development. Antengene's successful debut in the Hong Kong stock market shows global investors' profound recognition for our strategic model, growth potential, management team and product pipeline. By adopting the differentiated development approach and grasping the hot spots at the cutting edge of R&D, we will persevere in discovering, developing and commercializing novel oncology therapies with novel mechanisms so as to address unmet clinical needs in APAC and other parts of the world."